PropertyValue
?:abstract
  • INTRODUCTION: We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus. METHODS: This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group. RESULTS: Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%). DISCUSSION: Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.
?:creator
?:doi
  • 10.14309/ajg.0000000000000828
?:doi
?:journal
  • Am_J_Gastroenterol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/cf90b611ea11cf857f8d8b9338676c330581f49c.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7473797.xml.json
?:pmcid
?:pmid
?:pmid
  • 32858566.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice
?:type
?:year
  • 2020-08-27

Metadata

Anon_0  
expand all